Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing

NCT04213326 · View on ClinicalTrials.gov ↗

Study Summary

This is a prospective, observational study of 1,000 subjects with known or suspected cancer and 2,000 subjects with no known cancer. Potential participants will be asked questions to confirm their eligibility by a nurse navigator, study staff member, or physician. Informed consent will be carried out for eligible subjects in accordance with applicable federal regulations and International Council for Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines. Subjects will then complete a survey, and study staff will draw 60 mL of blood and measure the height and weight of the subject. Where available, data from the medical records of the cancer subjects will reviewed and collected. In addition, non-cancer subjects will be requested to allow access to their medical records as an optional portion of their informed consent.

Conditions Studied

Study Locations (14)

Florida

  • Sarah Cannon — Fort Walton Beach
  • Sarah Cannon — Ocala
  • Sarah Cannon — Pensacola

Georgia

  • Sarah Cannon — Augusta
  • Sarah Cannon — Macon
  • Sarah Cannon — Savannah

Kansas

  • Sarah Cannon — Kansas City
  • Sarah Cannon — Overland Park

California

  • Sarah Cannon — Thousand Oaks

Colorado

  • Sarah Cannon — Denver

Missouri

  • Sarah Cannon — Independence

Nevada

  • Sarah Cannon — Las Vegas

Tennessee

  • Sarah Cannon — Nashville

Trial Details

FieldValue
Enrollment Target 6,400 participants
Start Date 2019-11-18
Est. Completion 2021-01-29

Sponsor

Exact Sciences Corporation

42 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04213326

The ClinicalTrials.gov registry entry for NCT04213326 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 6,400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exact Sciences Corporation, which has 42 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Early Cancer Detection appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04213326 reports 14 study locations spanning 9 distinct geographic areas — top geographies include Florida, Georgia, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04213326 about?

NCT04213326 is a clinical study titled "Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing". This is a prospective, observational study of 1,000 subjects with known or suspected cancer and 2,000 subjects with no known cancer. Potential participants will be asked questions to confirm their eligibility by a nurse navigator, study staff member, or physician. Informed consent will be carried ...

What is the current status of trial NCT04213326?

This trial is currently completed. The enrollment target is 6,400 participants. The study started on 2019-11-18. Estimated completion is 2021-01-29.

What conditions does trial NCT04213326 study?

This clinical trial studies the following conditions: Early Cancer Detection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT04213326?

This trial is sponsored by Exact Sciences Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04213326 being conducted?

This trial has 14 study locations across California, Colorado, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial